Skip to main content
ST PHARM CO., LTD. logo

ST PHARM CO., LTD. — Investor Relations & Filings

Ticker · 237690 ISIN · KR7237690003 KO Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2025-09-08 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 237690

About ST PHARM CO., LTD.

https://www.stpharm.co.kr/en

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Recent filings

Filing Released Lang Actions
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is an official regulatory filing from ST Pharm regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the number of shares issued, the conversion price, and the impact on the total number of shares. This type of corporate action, involving the conversion of debt into equity, falls under capital structure changes and share issuance, which is best classified as 'Share Issue/Capital Change' (SHA).
2025-09-08 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). It contains detailed financial data, business operations, production capacity, and asset information for the fiscal year 2024. Since it is a comprehensive annual filing containing substantive financial statements and analysis, it is classified as an Annual Report. FY 2024
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for ST Pharm Co., Ltd. for the period ending June 30, 2025. It contains comprehensive financial data, business operations, management discussion, and capital structure details. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) containing actual financial statements and analysis is classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It specifies the date, location, purpose, and method of the event. It does not contain the actual presentation slides or the full financial report, but rather serves as a notification of the event and the availability of materials on the company's website. According to the 'Menu vs Meal' rule, this is an announcement of an event/report, fitting the criteria for a Regulatory Filing (RNS) or a general announcement.
2025-08-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., employee stock ownership deposits), and collateral agreements. This corresponds to the 'Major Shareholding Notification' category.
2025-07-25 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for ST Pharm, detailing quarterly financial performance (revenue, operating profit, net income) for the second quarter of 2025. It provides key financial highlights and is intended for investors and analysts. As it is an initial announcement of quarterly financial results rather than a full interim report or a report publication announcement, it fits the definition of an Earnings Release (ER). Q2 2025
2025-07-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.